Chromatin-Modifying Agents for Epigenetic Reprogramming and Endogenous Neural Stem Cell-Mediated Repair in Stroke

Irfan A. Qureshi, Mark F. Mehler

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The recent explosion of interest in epigenetics and chromatin biology has made a significant impact on our understanding of the pathophysiology of cerebral ischemia and led to the identification of new treatment strategies for stroke, such as those that employ histone deacetylase inhibitors. These are key advances; however, the rapid pace of discovery in chromatin biology and innovation in the development of chromatin-modifying agents implies there are emerging classes of drugs that may also have potential benefits in stroke. Herein, we discuss how various chromatin regulatory factors and their recently identified inhibitors may serve as drug targets and therapeutic agents for stroke, respectively. These factors primarily include members of the repressor element-1 silencing transcription factor (REST)/neuron-restrictive silencer factor macromolecular complex, polycomb group (PcG) proteins, and associated chromatin remodeling factors, which have been linked to the pathophysiology of cerebral ischemia. Further, we suggest that, because of the key roles played by REST, PcG proteins and other chromatin remodeling factors in neural stem and progenitor cell (NSPC) biology, chromatinmodifying agents can be utilized not only to mitigate ischemic injury directly but also potentially to promote endogenous NSPC-mediated brain repair mechanisms.

Original languageEnglish (US)
Pages (from-to)7-16
Number of pages10
JournalTranslational Stroke Research
Volume2
Issue number1
DOIs
StatePublished - Mar 2011

Fingerprint

Neural Stem Cells
Epigenomics
Chromatin
Transcriptional Silencer Elements
Stroke
Polycomb-Group Proteins
Chromatin Assembly and Disassembly
Brain Ischemia
Transcription Factors
Stem Cells
Macromolecular Substances
Histone Deacetylase Inhibitors
Explosions
Pharmaceutical Preparations
Cell Biology
Wounds and Injuries
Brain
Therapeutics

Keywords

  • Cerebral ischemia
  • Chromatin-modifying agent
  • Epigenetic reprogramming
  • Histone modification
  • Neural stem cell
  • Polycomb group
  • REST/NRSF
  • Stroke

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Cardiology and Cardiovascular Medicine

Cite this

Chromatin-Modifying Agents for Epigenetic Reprogramming and Endogenous Neural Stem Cell-Mediated Repair in Stroke. / Qureshi, Irfan A.; Mehler, Mark F.

In: Translational Stroke Research, Vol. 2, No. 1, 03.2011, p. 7-16.

Research output: Contribution to journalArticle

@article{f131a29f591c43c98b345b9b8bd1d943,
title = "Chromatin-Modifying Agents for Epigenetic Reprogramming and Endogenous Neural Stem Cell-Mediated Repair in Stroke",
abstract = "The recent explosion of interest in epigenetics and chromatin biology has made a significant impact on our understanding of the pathophysiology of cerebral ischemia and led to the identification of new treatment strategies for stroke, such as those that employ histone deacetylase inhibitors. These are key advances; however, the rapid pace of discovery in chromatin biology and innovation in the development of chromatin-modifying agents implies there are emerging classes of drugs that may also have potential benefits in stroke. Herein, we discuss how various chromatin regulatory factors and their recently identified inhibitors may serve as drug targets and therapeutic agents for stroke, respectively. These factors primarily include members of the repressor element-1 silencing transcription factor (REST)/neuron-restrictive silencer factor macromolecular complex, polycomb group (PcG) proteins, and associated chromatin remodeling factors, which have been linked to the pathophysiology of cerebral ischemia. Further, we suggest that, because of the key roles played by REST, PcG proteins and other chromatin remodeling factors in neural stem and progenitor cell (NSPC) biology, chromatinmodifying agents can be utilized not only to mitigate ischemic injury directly but also potentially to promote endogenous NSPC-mediated brain repair mechanisms.",
keywords = "Cerebral ischemia, Chromatin-modifying agent, Epigenetic reprogramming, Histone modification, Neural stem cell, Polycomb group, REST/NRSF, Stroke",
author = "Qureshi, {Irfan A.} and Mehler, {Mark F.}",
year = "2011",
month = "3",
doi = "10.1007/s12975-010-0051-3",
language = "English (US)",
volume = "2",
pages = "7--16",
journal = "Translational Stroke Research",
issn = "1868-4483",
publisher = "Springer US",
number = "1",

}

TY - JOUR

T1 - Chromatin-Modifying Agents for Epigenetic Reprogramming and Endogenous Neural Stem Cell-Mediated Repair in Stroke

AU - Qureshi, Irfan A.

AU - Mehler, Mark F.

PY - 2011/3

Y1 - 2011/3

N2 - The recent explosion of interest in epigenetics and chromatin biology has made a significant impact on our understanding of the pathophysiology of cerebral ischemia and led to the identification of new treatment strategies for stroke, such as those that employ histone deacetylase inhibitors. These are key advances; however, the rapid pace of discovery in chromatin biology and innovation in the development of chromatin-modifying agents implies there are emerging classes of drugs that may also have potential benefits in stroke. Herein, we discuss how various chromatin regulatory factors and their recently identified inhibitors may serve as drug targets and therapeutic agents for stroke, respectively. These factors primarily include members of the repressor element-1 silencing transcription factor (REST)/neuron-restrictive silencer factor macromolecular complex, polycomb group (PcG) proteins, and associated chromatin remodeling factors, which have been linked to the pathophysiology of cerebral ischemia. Further, we suggest that, because of the key roles played by REST, PcG proteins and other chromatin remodeling factors in neural stem and progenitor cell (NSPC) biology, chromatinmodifying agents can be utilized not only to mitigate ischemic injury directly but also potentially to promote endogenous NSPC-mediated brain repair mechanisms.

AB - The recent explosion of interest in epigenetics and chromatin biology has made a significant impact on our understanding of the pathophysiology of cerebral ischemia and led to the identification of new treatment strategies for stroke, such as those that employ histone deacetylase inhibitors. These are key advances; however, the rapid pace of discovery in chromatin biology and innovation in the development of chromatin-modifying agents implies there are emerging classes of drugs that may also have potential benefits in stroke. Herein, we discuss how various chromatin regulatory factors and their recently identified inhibitors may serve as drug targets and therapeutic agents for stroke, respectively. These factors primarily include members of the repressor element-1 silencing transcription factor (REST)/neuron-restrictive silencer factor macromolecular complex, polycomb group (PcG) proteins, and associated chromatin remodeling factors, which have been linked to the pathophysiology of cerebral ischemia. Further, we suggest that, because of the key roles played by REST, PcG proteins and other chromatin remodeling factors in neural stem and progenitor cell (NSPC) biology, chromatinmodifying agents can be utilized not only to mitigate ischemic injury directly but also potentially to promote endogenous NSPC-mediated brain repair mechanisms.

KW - Cerebral ischemia

KW - Chromatin-modifying agent

KW - Epigenetic reprogramming

KW - Histone modification

KW - Neural stem cell

KW - Polycomb group

KW - REST/NRSF

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=79951513844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951513844&partnerID=8YFLogxK

U2 - 10.1007/s12975-010-0051-3

DO - 10.1007/s12975-010-0051-3

M3 - Article

VL - 2

SP - 7

EP - 16

JO - Translational Stroke Research

JF - Translational Stroke Research

SN - 1868-4483

IS - 1

ER -